When you are talking about a drug target such as CD137—as opposed to an endogenous protein such as antithrombin or FVIIa—the entire development program could be characterized as “tweaking.”
I should have said that GTC’s business model for drugs that are based on endogenous proteins is to avoid tweaking and produce proteins that are as close as possible to the endogenous ones. This contrasts with the goal of a company such as MAXY, who is trying to use proprietary technology to make better or safer versions of such proteins. Both business models have merit, but GTC’s is much less risky, IMO.
Market Data 
Markets 
AI
